Metelitsa V I, Martsevich S Iu, Piotrovskiĭ V K, Blagodatskikh S V, Riabokon' O S
Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR. 1986;9(2):20-4.
The efficacy of dinitrosorbilong (DNL)--a new long-acting isosorbid dinitrate (IDN) preparation applied to the gum--was evaluated in 72 coronary patients with stable angina of effort. Repeated treadmill tests revealed antianginal effect of DNL exceeding 8 hours. The degree and duration of DNL action significantly surpassed those of conventional oral IDN tablets and of some other long-acting IDN preparations. The results of pharmacokinetic studies show that DNL bioavailability is 491 +/- 240% as compared to conventional oral IDN tablets. Regular 7-day DNL administration resulted in a significant decrease in the frequency of anginal attacks and in the daily consumption of nitroglycerin tablets as compared not only to the control period but also to the period of conventional IDN tablet therapy.
对72例劳力性稳定型心绞痛冠心病患者评估了二硝索比龙（DNL）——一种新的应用于牙龈的长效异山梨醇二硝酸酯（IDN）制剂——的疗效。重复进行的平板运动试验显示DNL的抗心绞痛作用超过8小时。DNL作用的程度和持续时间显著超过传统口服IDN片剂及其他一些长效IDN制剂。药代动力学研究结果表明，与传统口服IDN片剂相比，DNL的生物利用度为491±240%。与对照组以及传统IDN片剂治疗期相比，连续7天规律服用DNL可使心绞痛发作频率和硝酸甘油片的每日用量显著减少。
